ABSTRACT
Objectives:
The fixed dose combination of saxagliptin and dapagliflozin is a recently approved antidiabetic medication. It is marketed under the brand name Qtern. The aim of this study was to develop a simple, rapid, sensitive, and validated isocratic reversed phase-high performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of saxagliptin and dapagliflozin in human plasma using linagliptin as internal standard as per US-Food and Drug Administration guidelines.
Materials and Methods:
The method was performed on a Waters 2695 HPLC equipped with a quaternary pump. The analyte separation was achieved using an Eclipse XDB C18 (150 × 4.6 mm × 5 µm) column with a mobile phase consisting of 0.1% ortho phosphoric acid and acetonitrile (50:50) with pH adjusted to 5.0 at 1 mL/min flow rate.
Results:
The analyte was detected at 254 nm. The retention time of the internal standard, saxagliptin, and dapagliflozin was 2.746, 5.173, and 7.218 min, respectively. The peaks were found to be free of interference. The method was validated over a dynamic linear range of 0.01 to 0.5 μg/mL and 0.05 to 2 μg/mL for saxagliptin and dapagliflozin, respectively, with a correlation coefficient of 0.998. The precision and accuracy of samples of six replicate measurements at lower limits of quantification level were within the limits. The analytes were found to be stable in human plasma at -28°C for 37 days.
Conclusion:
The stability, sensitivity, specificity, and reproducibility of this method make it appropriate for the determination of saxagliptin and dapagliflozin in human plasma.
INTRODUCTION
The combination of saxagliptin and dapagliflozin has the potential to confer significant benefits in glycaemic control without the risk of weight gain and hypoglycemia, which may be associated with other medications used to treat type 2 diabetes.1 The fixed dose combination containing 10 mg of dapagliflozin and 5 mg of saxagliptin was recently approved by the US-Food and Drug Administration (FDA) for adults with type-2 diabetes. The combination was available under the brand name Qtern.2 Dapagliflozin belongs to the sodium glucose co-transporter-2 inhibitors with the chemical name (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl) tetrahydro-2H-pyran-3,4,5-triol (Figure 1a).3,4,5,6
Saxagliptin belongs to the class of drugs inhibiting the enzyme dipeptidyl-peptidase-4. This class of compound works by stimulating glucose-dependent insulin release. Chemically, it is (1S,3S,5S)-2-((2S)-amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0) hexane-3-carbonitrile (Figure 1b) and has the molecular formula C18H25N3O2.7,8,9 A review of the literature revealed that a few analytical methods like LC-Mass spectrometry,10,11 HPLC,12,13,14,15,16,17,18,19 and spectroscopic methods20,21 are available for the estimation of these drugs, either individually or in combination with other diabetic drugs like metformin.22,23,24,25,26 The present work aimed to develop a simple, rapid, and accurate method for the estimation of dapagliflozin and saxagliptin in human plasma, as per US-FDA guidelines.27 Moreover, the present method is the first for the estimation of this combination in a biological matrix.
MATERIALS AND METHODS
Reagents and chemicals
The pure drug samples of saxagliptin and dapagliflozin were purchased from Selleckchem.com LLC, supplied by Pro Lab Marketing. HPLC grade acetonitrile, HPLC grade methanol, and all other chemicals were obtained from Merck Chemical Division, Mumbai. HPLC grade water obtained from the Milli-Q water purification system was used throughout the study.
Instrumentation
Chromatography was performed with a Waters 2695 HPLC provided with a quaternary pump, auto-sampler, column oven, degasser, and 2996 PDA detector and with Empower-2 software.
Chromatographic conditions
The separation was achieved by isocratic elution using an Eclipse XDB C18 column (150 × 4.6 mm × 5 µm) with a mobile phase consisting of 0.1% orthophosphoric acid and acetonitrile (50:50) with pH adjusted to 4.5. The separation was achieved within 10 min at 254 nm using a 1 mL/min flow rate. The sample dilution was carried out using water:acetonitrile (50:50 ratio) as diluent.
Preparation of internal standard
The working internal standard was prepared by transferring 10 mg of linagliptin to a 10 mL volumetric flask; the final volume was completed using the diluent. From the resulting stock, 10 µg/mL solution was prepared by further dilutions.
Preparation of calibration and quality control solutions
The stock solutions of saxagliptin and dapagliflozin were prepared individually by dissolving 10 mg of the drug in 10 mL of diluent to obtain a 1 mg/mL concentration of each analyte. The stock solution was further diluted to prepare working standards. The calibration and quality control samples were obtained by spiking 10 µL of the above-prepared solutions of each analyte into 250 µL of plasma containing 50 µL of the internal standard. This resulted in final concentrations of saxagliptin and dapagliflozin of 0.01 µg/mL to 0.50 µg/mL and 0.05 µg/mL to 2.00 µg/mL, respectively, after spiking them into the plasma.
Sample preparation and extraction
The standard plasma samples, containing 10 µL of each analyte and 50 µL of internal standard (10 µg/mL), were mixed with 2 mL of acetonitrile. The sample tubes were vortexed for 2 min and were then centrifuged at 3200 rpm for 3 min. The resultant organic layer was used for analysis.
Method validation
A thorough and complete method validation was performed following the US-FDA guidelines. The method was validated for system suitability, auto-sampler carryover, specificity and screening of the biological matrix, sensitivity, matrix effect, linearity, precision and accuracy, recovery of the analyte and internal standard, ruggedness, reinjection reproducibility, and stability. The stability studies included bench top, freeze-thaw, and long-term stability at -28°C and -80°C.
Specificity
Specificity of the biological matrix was assessed and screening was performed using six blank standards and lower limit of quantification (LLOQ) level samples. All of the samples were checked to determine the extent of interference by the plasma components with the analyte and internal standard.
Calibration curve
The linearity of the method was determined by analysis of the standard plots associated with an eight-point standard calibration curve. Eight concentrations of saxagliptin and dapagliflozin ranging from 0.01 to 0.50 µg/mL and 0.05 to 2.00 µg/mL, respectively, were used, which included the LLOQ, low quality control (LQC), medium quality control (MQC), high quality control (HQC), and upper limit of quantification (ULOQ). The calibration curve was constructed by plotting the peak area ratio of the analytes to the internal standard against standard concentrations. The percentage difference of back-calculated concentrations to the nominal concentration (distribution of the residuals) was determined to validate the correlation. The acceptance criterion for the calibration model applied if residuals were within 15% for all calibration levels except LLOQ. Correlation coefficient, slope, and intercept were determined to evaluate the calibration curve.
Accuracy and precision
Intraday precision and accuracy were assessed at the lower, middle, high, and lower limit of quantification quality control samples LQC, MQC, HQC, and LLOQ in six replicates for both of the analytes, while interday precision and accuracy were assessed for three consecutive days by using quality control samples. Mean values were obtained for calculated drug concentration over these batches. The accuracy of the analytical method describes the closeness of the mean test results obtained by the method to the actual value of the analyte and was determined by replicate analysis of the analyte. The accuracy and precision were calculated and expressed in terms of % mean accuracy and coefficient of variation (% CV), respectively.
Recovery
Recovery of the analytes from the extraction procedure was performed at LQC, MQC, and HQC levels. It was assessed by comparing the peak area of the extracted samples (spiked before extraction) to the peak area of the unextracted samples (quality control working solutions spiked in extracted plasma).
Ruggedness
Ruggedness refers to the ability of an analytical method to remain unaffected by small variations. Parameters were used to evaluate the constancy of the results when external factors such as analyst, laboratory, instrument, reagents, and days were varied. The ruggedness of the method assessed was determined using different analysts and on different instruments of the same make.
Sensitivity
Sensitivity is defined as the lowest analyte concentration that can be measured with acceptable accuracy and precision. Sensitivity experiments were carried out by using six replicates of the LLOQ level sample to determine the lowest limit of detection, the % mean accuracy, and the % CV.
Stability
Stability studies were performed by keeping replicates of plasma samples at room temperature for 24 h. The freeze-thaw stability of the drugs in plasma samples was studied over three freeze-thaw cycles, by thawing at room temperature for 2-3 h and refreezing for 12-24 h. The stability of the drugs in plasma was also tested after storage at -80°C. The concentration of the drugs after each storage period was related to the initial analyte concentrations of freshly prepared samples. Samples were considered stable if the assay values were within the acceptable limits of accuracy and precision.
RESULTS
Method optimization
To obtain the best results, different mobile phase compositions containing phosphate buffer systems with varied pH and organic solvents like methanol and acetonitrile were used to provide adequate sensitivity and selectivity in a short separation time. The best results were obtained with the mobile phase consisting of 0.1% phosphoric acid (pH 4.5) and acetonitrile (50:50) with a flow rate of 1 mL/min. The detection was monitored at 254 nm. With these conditions, the retention times of linagliptin, saxagliptin, and dapagliflozin were found to be 2.784, 5.295, and 7.204 min, respectively.
Method validation
System suitability and auto-sampler carryover
System suitability was assessed using the MQC level sample as six homogenous injections. The % CV for retention time and response was calculated. The results are presented in Table 1. The values obtained were lower than 1%, which shows the suitability of the system for the analysis of the selected combination in human plasma.
Auto-sample carryover was assessed by ULOQ and LLOQ levels to ensure that it did not affect the accuracy and precision. No carryover was observed.
Linearity
The ratio of peak area of analyte to internal standard was used for construction of the calibration curve. The linearity of saxagliptin and dapagliflozin was established by an eight-point calibration curve. The most variable regression equation of the calibration curve for saxagliptin and dapagliflozin was y=0.126(±0.02)x + 0.003 and y=0.53(±0.02)x - 0.002, respectively. The linearity of the calibration graph was validated by the high value of the correlation coefficient with an average value of 0.996 and 0.998 for saxagliptin and dapagliflozin, respectively. The standard curves of saxagliptin and dapagliflozin are presented in Figure 2.
Precision and accuracy
The precision and accuracy of the methods were assessed by analyzing six replicates of LLOQ, LQC, MQC, and HQC levels. The accuracy of the method was determined by calculating the % mean accuracy and the precision by calculating relative standard deviation. The data regarding precision and accuracy are summarized in Table 2. The chromatogram of quality control samples is shown in Figure 3. The % mean accuracy of saxagliptin and dapagliflozin ranged from 98.33 to 101.29 and from 98.43 to 103.28, respectively.
Recovery
Recovery of saxagliptin and dapagliflozin was determined by comparing the mean peak areas of six replicates of three quality control samples (HQC, MQC, and LQC) with the mean peak areas of unextracted quality control samples at the same level. The results of the recovery study are given in Table 3. The results are within the acceptance limits.
Ruggedness
The present method showed good ruggedness when it was performed using different analysts and on different instruments of the same make. The results of the ruggedness study were found to be within acceptable limits, proving no significant analyst-to-analyst and instrument-to-instrument variation and hence the ruggedness of the method. The results are presented in Table 4.
Stability
The stability of the analytes in human plasma was assessed by analysis of six replicates of quality control samples at low and high concentration levels at room temperature over 24 h (bench-top stability). The measured concentrations were compared with those of freshly prepared and processed samples. The results obtained indicated that the two drugs saxagliptin and dapagliflozin were stable for at least 24 h in human plasma when retained at room temperature. On the other hand, the results obtained for quality control samples subjected to long-term storage at -28°C for 37 days and at -80°C indicate the stability of analytes in human plasma. In contrast, the freeze-thaw stability determined by using LLOQ, LQC, MQC, and HQC level of samples also indicated the stability of analytes in human plasma. The results obtained are compiled in Table 5.
DISCUSSION
Since there is no reported sensitive method for the estimation of saxagliptin and dapagliflozin in combination, the validated LC-UV method was developed for routine analysis in a biological matrix. Moreover, the available methods were developed to assess drugs either individually or in combination. Therefore, there is a need to develop an analytical method for the estimation of this combination. The current method aims to develop a simple, accurate, and reliable method for the simultaneous estimation of saxagliptin and dapagliflozin in human plasma. Good resolution and minimum tailing were achieved using this method. The method used simple single-step protein precipitation with acetonitrile and provided good selectivity when tested for peak interference from endogenous sources by comparing the blank chromatogram with quality control samples. The retention times of the internal standard, saxagliptin, and dapagliflozin were found to be 2.746, 5.173, and 7.218 min, respectively. The developed method proved to be rugged and had adequate recovery and no matrix effect. The recovery was determined by comparing the extracted sample with the unextracted samples at three quality control sample levels, i.e., LQC, MQC, and LLOQ. The results were found to be within acceptable limits. The linearity of the method was tested by developing an eight-point calibration curve that included all quality control sample concentrations. The linear range for saxagliptin and dapagliflozin was found to be 0.01 to 0.50 µg/mL and 0.05 to 2.00 µg/mL, respectively. The regression coefficient for saxagliptin and dapagliflozin was 0.996 and 0.998, respectively. The linear range and statistical parameters prove that the developed method is more sensitive than the reported LC coupled with a PDA detector. Using the stability studies, it was found that the analytes were stable in plasma throughout the analysis period. The stability data were built by comparing the stability samples with freshly prepared samples. On the other hand, long-term stability was established by subjecting quality control samples to -28°C for 37 days and to -80°C. The results obtained indicate that the method is sensitive, reliable, and cost-effective. Furthermore, the method can be made applicable to pharmacokinetic estimation.
CONCLUSIONS
The proposed method for the estimation of a saxagliptin and dapagliflozin binary mixture in human plasma is simple, accurate, and reliable. The single-step protein precipitation, short runtime of 10 min, and isocratic elution make the method economical and suitable for the analysis of a large number of samples. The method has been validated as per the requirements of the US-FDA. It can therefore be concluded that the method is suitable for the routine quantification of saxagliptin and dapagliflozin in human plasma.